EAPB02303

1. EAPB02303 inhibits insulin/IGF-1 signalling in worms.

   “EAPB02303 potently reduced the activity of IIS and Ras-MAPK signaling in C. elegans.”

   Model organisms

   Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model

   International journal of molecular sciences·16 Jul 2024

More on Insulin/IGF-1 signalling

1. EAPB02303 decreases multivulva phenotype in worms.

   “EAPB02303 significantly reduced the multivulva phenotype in let-60/Ras mutant strains MT2124 and MT4698”

   Model organismslet-60/Ras mutant strains MT2124 and MT4698

   Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model

   International journal of molecular sciences·16 Jul 2024

1. EAPB02303 activates daf-16 in worms.

   “led to the nuclear translocation and subsequent activation of transcription factor DAF-16”

   Model organismsMicromolar doses

   Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model

   International journal of molecular sciences·16 Jul 2024

More on daf-16

1. EAPB02303 extends lifespan in worms.

   “Micromolar doses of EAPB02303 significantly enhanced longevity of N2 strain”

   Model organismsN2 wild-type strainMicromolar doses

   Uncovering the Molecular Pathways Implicated in the Anti-Cancer Activity of the Imidazoquinoxaline Derivative EAPB02303 Using a Caenorhabditis elegans Model

   International journal of molecular sciences·16 Jul 2024